Annual Report

Kristin Richeimer
Kristin Richeimer
Heather Wakelee
Heather Wakelee, MD

Welcome Letter

Dear Colleagues and Friends, Welcome to the 2021 IASLC Annual Report! As we look back on 2021, we see how our lives, our Association and the lung cancer community as a whole continued to be impacted by the pandemic. While we hoped that 2021 would bring us back together to meet in person, that was not to be. However, IASLC was able to produce extraordinary publications and education offerings within a virtual platform.

IASLC Year in Review

Dr. Heather Wakelee welcomes you to the IASLC 2021 Annual Report. 

IASLC's International and Multidisciplinary Membership

Despite the worldwide focus on COVID-19, IASLC members from all corners of the world continued to drive scientific advancements and collaboration. IASLC members worked in incredibly difficult circumstances during the pandemic. Furthering the mission of the IASLC, members were supported in these global efforts by receiving discounted registration fees to meetings and educational events, complimentary access to the Journal of Thoracic Oncology and discounted publication fees for the open-access IASLC Journal, JTO Clinical and Research Reports. (JTO CRR)

Members By Country/Region

Members by Primary Specialty

Labels Values
Medical Oncology 1984
Thoracic Surgery 862
Other/Unknown 613
Pulmonary Medicine 593
Cancer Research 412
Radiation Oncology 389
Pathology 335
Advocacy 270
Biotech/Pharmaceutical 170
Nursing 93
Diagnostic Radiology 90
Pharmacy 51
Biostatistics 40
Smoking Cessation 11
Hemotology 8
Resp Therapy/Physiotherapy 6

Professional Activity/Practice

Labels Values
Academic Medical Center 2966
Other/Unknown 830
Cancer Center 655
Pharmaceutical/Biotech 554
Private Practice (Hospital) 216
Private Practice (Office) 202
Training Program 147
Non-Profit or Advocacy 115
Laboratory Research 101
Government Agency 83
Administration 33
Retired 25


Serving on an IASLC committee in a volunteer capacity, members contribute their specialized skills and talents to help define the work of the organization, develop educational content, shape the association's messaging, plan annual meetings, contribute to publications authored by the IASLC, and more.

Committee Chair:
Fiona McDonald
The advanced radiation technology (ART) committee focuses on educating members about emerging techniques, technologies and strategies for treating thoracic malignancies.
Committee Chair:
Brendon Stiles
The Communications Committee develops campaigns to increase IASLC brand recognition and credibility while educating the public about complex lung and thoracic cancer issues. The committee also reviews articles for publication in the Journal of Thoracic Oncology and determines which pieces to promote to the media.
Committee Chair:
Christian Rolfo
The Education Committee plans and implements educational activities in accordance with IASLC’s mission of providing education and information about lung cancer and other thoracic malignancies to IASLC members, to the medical community at large, and to the public.
Committee Chair:
Paul Baas
Mesothelioma is a rare tumor with limited options that has seen several research updates in 2020, many of which were spearheaded by members of this committee.
Committee Chair:
Wendy Cooper
For more than 35 years, the IASLC Pathology Committee has played a fundamental role in fulfilling core aspects of the association's mission.
Committee Chair:
Stephen Lam
The Screening and Early Detection Committee provides leadership and oversight of IASLC activities in these areas. The committee works with appropriate internal committees to enhance the quality and quantity of IASLC cancer prevention initiatives and provides leadership in partnership with other societies in the area of cancer prevention and screening.
Committee Chair:
Bill Evans
Improving patient care by raising awareness of cessation-related data and by provision of information regarding the latest and most successful cessation techniques for patients with lung cancer.
Committee Chair:
Ahmed Rabea
The Career Development and Fellowship Committee focuses on supporting the next generation of lung cancer specialists.
Committee Chair:
Apar Kishor Ganti
Committee Co-chair:
Nick Pavlakis
The Continuing Medical Education (CME) Committee oversees the educational program of IASLC to ensure that activities are planned and implemented in compliance with all ACCME Accreditation Requirements, including the ACCME Standards for Commercial Support℠. The CME Committee is also responsible for ensuring that IASLC’s CME activities meet the requirements of the American Medical Association Physician’s Recognition Award (AMA PRA).
Committee Chair:
Nan Wu
The Membership Committee review and recommend membership status requirements and benefits for all IASLC members. Members of this committee also strategize and implement tactics to increase and retain association membership in their area of specialty and region.
Committee Chair:
Maria Ftanou
The Nursing & Allied Health Professionals Committee (NAHP) within IASLC is comprised of multidisciplinary clinicians and researchers each with a unique perspective, committed to advancing the education of both practitioners and patients in thoracic oncology. Our goal is to improve and optimize outcomes for oncology patients and families across the cancer trajectory through diagnosis, treatment, survivorship and end of life.
Committee Chair:
Jill Feldman
The Patient Advocates Committee ensures that the IASLC addresses the informational needs of the public, advocates and patients living with lung and thoracic cancers. This committee also comprehensively addresses the educational and related needs of the public as an important constituency in the work of the association.
Committee Chair:
Hisao Asamura
Staging lung cancer and other thoracic malignancies accurately is critical in deciding treatment regimens and ensures best standardized care for patients worldwide. The IASLC Staging Project is a global effort to study and improve the current staging system for lung cancer, as well as for thymic and esophageal cancers and mesothelioma.

Education and Conferences

This year it was imperative for the IASLC to execute impactful and interactive virtual conferences, given the continued, serious public health concerns and restrictions on travel and in-person gatherings due to COVID-19. As a result, the IASLC executed a portfolio of six fully virtual conferences with pre-recorded, live, and on-demand content. The WCLC 2021 offered Meet the Expert sessions and Brain Exchange sessions, offering the opportunity for greater interactivity, engagement, and member connectivity in a virtual setting.

2021 Meetings

IASLC 2021 World Conference on Lung Cancer

The IASLC made an early decision to execute the 2021 World Conference on Lung Cancer (WCLC 2021) as a fully virtual event. The WCLC Conference Chairs, Drs. David Harpole, Thomas Stinchcombe, and Kristin Higgins continued the IASLC’s tradition of delivering high-quality educational programs marked by practice-changing abstracts.

WCLC 2021 Quick Facts

Media Coverage

Award Winners

Scientific Affairs

Journal of Thoracic Oncology

The Journal of Thoracic Oncology's (JTO) influence on the field is represented by its increased impact factor, which has climbed dramatically in recent years. The 2020 impact factor for JTO is 15.609 up from 13.357 in 2019. This moves the journal’s rank to 4th among 64 respiratory medicine journals and 13th among 242 oncology journals.

JTO and JTO CRR Logos

JTO Clinical and Research Reports

JTO Clinical and Research Reports (JTO CRR) transitioned to article-based publishing and became a monthly publication in 2021. In 2021, JTO CRR articles became indexed and available through PubMed Central.

JTO Impact Factor on the Rise

Labels Values
2008 3.508
2009 4.547
2010 4.040
2011 3.661
2012 4.473
2013 5.8
2014 5.282
2015 5.040
2016 6.595
2017 10.336
2018 12.460
2019 13.357
2020 15.609
Journals adjei alex

It is generally difficult for organ-specific oncology journals to make a significant impact in the oncology publishing landscape. With an Impact Factor of 15.609, JTO is the leading journal in thoracic oncology and, in the top fifteen (ranked 14th) of all cancer journals,” said Editor-in-Chief, Dr. Alex A. Adjei, MD, Ph.D. “JTO’s emphasis on multidisciplinary research is one of its strengths and serves the broad community of researchers in this field. 

IASLC Technology and Media Initiatives

Patient Advocacy

The IASLC recognizes the importance and value that patients with lung cancer, their caregivers, and patient advocates bring to the lung cancer community and to the organization.

2021 Cancer Care Team Awards

The 2021 IASLC Cancer Care Team Award recognizes extraordinary patient care in the field of thoracic malignancies. Awardees are nominated by patients and their loved ones. 


  December 31 (Unaudited) 
  2021 2020
Program Revenues $12,78,644 $7,148,662
Membership Revenues $744,497 $632,870
Other Revenues $927,858 --
Total Revenues $14,465,999 $7,781,532
Direct Program Expenses $7,582,308 $4,584,120
G&A Expenses $5,115,252 $5,520,532
Total Expenses $12,697,560 $10,104,652
Operating Surplus(Deficit) $1,759,439 ($2,323,120)
Other Income/Expense  $950,000 $65,296



Revenue by Type

Labels Values
Conferences & Meetings 62%
Scientific Projects 9%
Publications 12%
Membership 5%
Fellowships 5%
Federal Grants 6%

Corporate Relations

To explore all the opportunities to engage with the IASLC please contact us at the button below. 

International Lung Cancer Foundation

2021 was the International Lung Cancer Foundation's (ILCF) most successful individual fundraising year ever. We are grateful to each individual who donated to support lung cancer research in 2021

Donation Sources

Labels Values
membership Renewals 5%
Online Donations 14%
Honoraria 6%
Meetings (not WCLC) 6%
WCLC 21%
Adi Gazdar Estate 48%